MedTrace Logo

Ocular Biodistribution Study for Topically Applied ESBA105

NCT00820014 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2010-09-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether ESBA105, a single-chain (scFv) antibody against TNF-alpha, efficiently penetrates into the anterior chamber and the vitreous body upon topical administration to the eye.

Conditions

  • Cataract

Interventions

DRUG

Placebo

Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery

Sponsors & Collaborators

  • ESBATech AG

    lead INDUSTRY

Principal Investigators

  • Michael A Thiel, MD, PhD · Kantonsspital Luzern, Augenklinik, CH-6000 Luzern 16, Switzerland

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820014 on ClinicalTrials.gov